On January 22, Chairman Waxman wrote to FDA Commissioner von Eschenbach requesting documents related to the FDA's draft guidance allowing drug companies to use journal articles to promote potentially dangerous off-label uses of drugs and medical devices without prior FDA review and approval. According to FDA minutes of a meeting, Dan Troy and other drug company representatives urged FDA to issue guidance to protect the companies from "Federal prosecutors pursuing distributors of this information for criminal conduct."

Documents and Links

- Letter to FDA Commissioner von Eschenbach
- FDA Response to November 30 Request for Documents
- Memorandum of April 13 FDA Meeting